Citrate-capped IrO2NPs were modified with anti-Apolipoprotein E antibodies (αApoE) for the detection of the ApoE alzheimer disease biomarker, with a detection limit of 68 ng mL−1. This evidence concerns the gene APOE and Alzheimer disease.